Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment
View Full Paper
Ask AI
Bookmark
Share
Key result
Hypertrophic cardiomyopathy is a relatively common inherited cardiomyopathy that can be effectively managed through genetic diagnosis, risk stratification, and targeted medical or invasive therapies.
Population
Individuals with hypertrophic cardiomyopathy
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports evidence-based HCM evaluation and therapy selection; leaves open prospective validation of emerging risk tools.
Structured PICO
P
Population
Individuals with hypertrophic cardiomyopathy
This review outlines an evidence-based approach to the diagnosis, risk stratification for sudden cardiac death, and medical or invasive management of hypertrophic cardiomyopathy.
Limitations
- Prospective randomized controlled trials are largely absent from the literature on hypertrophic cardiomyopathy.
- The pathways that lead from gene mutation to hypertrophy, restrictive physiology, and arrhythmias remain incompletely understood.
- There are no prospective data on reduction in mortality with the use of implantable cardioverter defibrillators in this population.
Cite This Study
Jacoby et al. (2012) conducted a review in Hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy is a relatively common inherited cardiomyopathy that can be effectively managed through genetic diagnosis, risk stratification, and targeted medical or invasive therapies.
Topics
View Full Paper
Ask AI
Bookmark
Share